Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Background Whether acetazolamide, a carbonic anhydrase inhibitor that reduces proximal
tubular sodium reabsorption, can improve the efficiency of loop diuretics, potentially leading …

Refractory congestion is common in acute and chronic heart failure, and it significantly
impacts functional class, renal function, hospital admissions, and survival. In this paper, the …

ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Aims To describe the baseline characteristics of participants in the Acetazolamide in
Decompensated Heart Failure with Volume Overload (ADVOR) trial and compare these with …

Background For patients with acute heart failure (AHF), substantial diuresis after
administration of loop diuretics is generally associated with better clinical outcomes but may …

Aims Insufficient diuretic response frequently occurs in patients admitted for acute heart
failure (HF) and is associated with worse clinical outcomes. Recent studies have shown that …

Aim Intrinsic renal sodium avidity (IRSA) is a hallmark feature of acute heart failure (AHF)
and can be measured by evaluating the urinary sodium (UNa) concentration. The aim of this …

Aims Cardiogenic shock (CS) is a life-threatening condition burdened by mortality in up to
50% of cases. Few recommendations exist with intermediate–low level of evidence on CS …